In the latest round of the cholesterol wars, Amgen (AMGN) (AMGN) is cutting the list price of its injectable cholesterol medicine by 60 percent from its original price tag, a move that the drug maker hopes will appease payers and lower out-of-pocket costs for many patients.

After launching Repatha at roughly $14,500, the company is now setting a wholesale price of $5,850 per year, but this remains well above the range recommended last year by a cost-effectiveness watchdog, except for a select group of high-risk patients. The price cut comes as the Trump administration leans on drug makers to hold the line on price hikes, although Amgen officials demurred when asked whether they were trying to win political brownie points.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy